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Abstract
Cardiokines play an essential role in maintaining normal cardiac functions and responding to acute myocardial injury.
Studies have demonstrated the heart itself is a signiﬁcant source of C1q/TNF-related protein 9 (CTRP9). However, the
biological role of cardiac-derived CTRP9 remains unclear. We hypothesize cardiac-derived CTRP9 responds to acute
myocardial ischemia/reperfusion (MI/R) injury as a cardiokine. We explored the role of cardiac-derived CTRP9 in MI/R
injury via genetic manipulation and a CTRP9-knockout (CTRP9-KO) animal model. Inhibition of cardiac CTRP9
exacerbated, whereas its overexpression ameliorated, left ventricular dysfunction and myocardial apoptosis.
Endothelial CTRP9 expression was unchanged while cardiomyocyte CTRP9 levels decreased after simulated ischemia/
`reperfusion (SI/R) in vitro. Cardiomyocyte CTRP9 overexpression inhibited SI/R-induced apoptosis, an effect abrogated
by CTRP9 antibody. Mechanistically, cardiac-derived CTRP9 activated anti-apoptotic signaling pathways and inhibited
endoplasmic reticulum (ER) stress-related apoptosis in MI/R injury. Notably, CTRP9 interacted with the ER molecular
chaperone calreticulin (CRT) located on the cell surface and in the cytoplasm of cardiomyocytes. The CTRP9–CRT
interaction activated the protein kinase A-cAMP response element binding protein (PKA-CREB) signaling pathway,
blocked by functional neutralization of the autocrine CTRP9. Inhibition of either CRT or PKA blunted cardiac-derived
CTRP9’s anti-apoptotic actions against MI/R injury. We further conﬁrmed these ﬁndings in CTRP9-KO rats. Together,
these results demonstrate that autocrine CTRP9 of cardiomyocyte origin protects against MI/R injury via CRT
association, activation of the PKA-CREB pathway, ultimately inhibiting cardiomyocyte apoptosis.

Introduction
Ischemic heart disease (IHD) is the leading cause of death
and disability worldwide1,2. Cardiokines are a group of
proteins present in secretomes produced by the heart3,4.

They maintain cardiac homeostasis and modulate pathological remodeling in response to stress via autocrine/
paracrine pathways5. Some cardiokines are secreted during
ischemic stress, and function to salvage viable myocardial
structure and function via anti-apoptotic and antiinﬂammatory properties6–9. These endogenous cardiokines may serve as novel therapeutic targets against IHD,
given their immediate response to acute myocardial injury3.
C1q/TNF-related protein 9 (CTRP9) is a member of
the adiponectin (APN) paralog CTRP family, initially
identiﬁed as an adipokine modulating metabolic and
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cardiovascular function. Circulating CTRP9 attenuates
myocardial ischemia/reperfusion (MI/R) injury, reverses
post-MI remodeling, and promotes vasorelaxation in an
endocrine fashion10–15. We and others demonstrated that
CTRP9 is highly expressed in the heart, nearly 1.6-fold of
circulating CTRP9 level14,16,17. However, myocardial
capillary endothelial cell-derived CTRP9 was shown
to trigger cardiomyocyte hypertrophy in a paracrine
manner17. The discrepancy in the regulation of myocardial
function by different origins of CTRP9 remains unexplained. Whether cardiac-derived CTRP9 protects against
MI/R injury (and if so, by what mechanisms) is unknown.
The aims of this study were (1) to determine the role of
cardiac-derived CTRP9 in MI/R injury; (2) to investigate
whether cardiac-derived CTRP9 regulates myocardial
dysfunction after MI/R in an autocrine or paracrine
manner; (3) to elucidate the underlying mechanisms
responsible for the actions of cardiac-derived CTRP9
upon MI/R injury.

Materials and methods
All experiments were approved by the Fourth Military
Medical University Committee on Animal Care. Eight- to
10-week-old C57BL/6J male mice and neonatal
Sprague–Dawley rats (1–2 days old) were provided by the
Experimental Animal Center of the Fourth Military
Medical University (Xi’an, China). The CTRP9-knockout
(KO) (on a Sprague–Dawley background) rats were generated by the K&D Gene Technology Co., Ltd (Wuhan,
China). Homozygous CTRP9-KO and littermate WT rats
were used in the present study. Baseline conditions of
CTRP9-KO rats were recorded prior to experiments.
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blot. Plasma CTRP9 was determined by Enzyme-Linked
Immunosorbent Assay (Aviscera Bioscience, SK00081-08)
to detect whether the lentivirus mediated a cardiacspeciﬁc CTRP9 overexpression (Supplemental Fig. 1D).
Animal model of MI/R

Seventy-two hours after intra-myocardial injection of
siRNA or lentivirus, mice and CTRP9-KO rats were
anesthetized with 2% isoﬂurane. The heart was exposed
by a left thoracic incision. Myocardial infarction was
produced by placing a 6.0 silk suture slipknot around the
left anterior descending coronary artery. After 30 min of
ischemia, the slipknot was released to allow reperfusion
for 3 or 24 h. Sham-operated mice/rats underwent left
thoracotomy only.
Echocardiographic analysis

Mice and CTRP9-KO rats were subjected to transthoracic echocardiography (VisualSonics VeVo 2100
Imaging System) for assessment of cardiac structure and
function after 24 h reperfusion. Echocardiography was
performed, and M-mode tracings were recorded.
Evans blue/TTC staining

After 24 h reperfusion, 1.5% Evans blue (Sigma-Aldrich,
E2129) was injected into the aorta. The heart was
removed and frozen at −80 °C immediately. Subsequently,
the heart was horizontally sectioned into 5–6 slices,
and incubated with 1% 2, 3, 5-triphenyl tetrazolium
chloride (TTC, Sigma-Aldrich, T8877) for 15 min at
37 °C. The left ventricular (LV) area, the area at risk
(AAR), and infarct area (IA) of each section was calculated
by Image J.

In vivo siRNA-mediated cardiac CTRP9 deﬁciency

CTRP9 Stealth RNAi (siCTRP9, 0.8 μg/μl, Invitrogen,
MSS248274) or non-speciﬁc control small interfering
RNA (siRNA) (NC, Invitrogen, 12935114) pre-mixed by
in vivo jet PEI (Genesee Scientiﬁc, 201-10G) were delivered via three separate intra-myocardial injections (by
32.5-gauge needle) to temporarily blanch the LV free wall
as described previously18,19. Western blot determined
knockdown efﬁciency 72 h later.

TUNEL staining

Mouse and CTRP9-KO rat hearts were perfused with
ice-cold phosphate-buffered saline and ﬁxed with 4%
paraformaldehyde, embedded in parafﬁn, and coronally
sectioned (3–6 μm thick). Three to ﬁve sections from each
heart were subjected to infarct area TUNEL (terminal
deoxynucleotidyl transferase dUTP nick-end labeling)
Staining Assay (Roche Diagnostics Corporation,
11684817910), as per the manufacturer’s protocol.

In vivo lentivirus-mediated cardiac CTRP9 overexpression

Green ﬂuorescent protein (GFP)-conjugated CTRP9
lentivirus (LV. CTRP9) or negative control (NC) lentivirus
(NC) were injected into the left ventricle of mice (30 μl)
and rats (100 μl) (Table 1). Frozen heart sections were
prepared after 72 h transfection. Lentiviral location was
assessed by staining with α-actin (Sigma-Aldrich, A2547)
or CD31 (Boster, BA0532) antibodies (Supplemental
Figs. 1B and 2A). Five sections from each heart were
examined by ﬂuorescence microscopy (Olympus, Japan).
The overexpression efﬁciency was assessed by Western
Ofﬁcial journal of the Cell Death Differentiation Association

Measurement of LDH release

Lactate dehydrogenase (LDH) activity in conditioned
medium and cell lysates were determined by the LDH
release assay (Institute of Jiancheng Bioengineering,
A020-2). The percentage of LDH release was calculated as
follows: “(A−B)/(C−B) × 100,” where A is the LDH
activity in conditioned medium, B is the LDH activity
in culture medium (without cells), and C is the
LDH activity in cell lysates, as per the manufacturer’s
protocol.

Zhao et al. Cell Death and Disease (2018)9:723
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Table 1 Lentivirus information
Gene

Lentivirus type

Sequence (5′–3′)

Titer

Negative control (NC)

LV5 (GFP&Puro)

TTCTCCGAACGTGTCACGT

1 × 108 Tu/ml

Negative control (NC)

LV10 (RFP&Puro)

TTCTCCGAACGTGTCACGT

1 × 108 Tu/ml

C1qtnf9 mus

LV5 (GFP&Puro)

Full sequence (NM_001191891.1)

1 × 109 Tu/ml

C1qtnf9 Rat

LV5 (GFP&Puro)

Full sequence (NM_183175.4)

1 × 109 Tu/ml

Calr-Rat-429

LV10 (RFP&Puro)

GCATGGAGACTCAGAATATAA

1 × 108 Tu/ml

Adipor1-Rat-1294

LV10 (RFP&Puro)

GGAATTCCGTTACGGCCTAGA

1 × 108 Tu/ml

All lentivirus were produced by Shanghai GenePharma Co., Ltd

Measurement of caspase-3 activity

Plasma membrane protein extraction

Caspase-3 activity was measured via a ﬂuorometric kit
(BD Biosciences, 556574). Brieﬂy, heart tissue or cultured
cardiomyocytes were lysed on ice. The supernatant was
collected. The reactions were performed in assay buffer
containing 10 mM dithiothreitol (DTT) and 50 µg proteins. The ﬂuorescence emission of the 7-amino-4-triﬂuoromethyl-coumarin (AFC) was measured via Spectra
Max-Plus microplate spectrophotometer (Molecular
Devices, excitation wavelength, 400 nm; emission wavelength, 505 nm). Caspase-3 activity was expressed as nmol
AFC/h/mg protein.

Plasma membrane proteins were extracted by
Plasma Membrane Protein Extraction Kit (Fisher
Scientiﬁc, P503) via methods slightly modiﬁed from the
manufacturer’s protocol. Brieﬂy, heart tissues (20–30 mg)
pre-mixed by 500 µL Buffer A were mechanically lysed
by Dounce homogenizer. After centrifugation, the
supernatant was transferred into a fresh microcentrifuge
tube and centrifuged at 100,000 × g, 4 °C for 1 h to extract
cytosolic proteins. The pellet was mixed with 500 µL
Buffer B and incubated at 4 °C for 30 min. The total
membrane protein fractions were gathered after 6000 × g
centrifugation at 4 °C for 10 min. Organelle membrane
proteins were extracted after 7800 × g centrifugation at
4 °C for 20 min, while plasma membrane proteins were
extracted after additional 16,000 ×g centrifugation at 4 °C
for 30 min.

Co-immunoprecipitation

The LV tissue lysate was incubated with pre-washed
Dynabeads® Protein G (Invitrogen, 10003D) or Protein
A (Invitrogen, 10006D) at 4 °C for 2 h. Beads were magnetically collected against the vessel wall. The supernatant
was then incubated with normal immunoglobulin G (IgG),
anti-CTRP9 (LifeSpan Biosciences, Inc., LS-C373857), or
anti-calreticulin (CRT) (Santa Cruz, sc-373863) primary
antibodies together with 15 μl pre-washed Dynabeads®
Protein G or Protein A at 4 °C overnight. The immunoprecipitated proteins were released from the beads using
elution buffer, and mixed with a loading buffer containing
100 mM DTT. Samples were boiled and analyzed by
Western blot.

Simulated ischemia/reperfusion

Normal culture medium was replaced by Hanks'
balanced salt solution (Gibco, 14175079). NCMs or C166
mouse embryonic yolk sac endothelial cells (MECs, purchased from ATCC) were placed in a Napco 8000WJ
hypoxia (1% O2, 5% CO2, 94% N2) incubator
(Thermo Fisher Scientiﬁc, Inc.). After 12 h of
hypoxia–hypoglycemic culture, cells were bathed again in
normal culture medium, and incubated for 3 or 6 additional hours in a normal CO2 incubator.

Analysis of colocalization by microscopy

Control and post-simulated ischemia/reperfusion (SI/R)
neonatal rat cardiomyocytes (NCMs) were ﬁxed by 4%
paraformaldehyde, and stained with rabbit anti-CTRP9
(LifeSpan Biosciences, Inc., LS-C373857) and mouse antiCRT (Abcam, ab22683) primary antibodies at 4 °C overnight. After washing, cells were stained with Alexa Fluor
488-conjugated goat anti-rabbit and Alexa Fluor 594conjugated goat anti-mouse secondary antibodies (Invitrogen, A-11008 and R37121). Fluorescent images were
obtained by laser scanning confocal microscopy (Fluo
View TM FV 1000, Olympus).
Ofﬁcial journal of the Cell Death Differentiation Association

Cell culture and treatments

Isolated NCMs were cultured in Dulbecco's modiﬁed
Eagle's medium/F12 (Gibco, 11320033) containing 10%
fetal bovine serum (Gibco, 10438026) to ~80% conﬂuence
(~5 × 104 cells) as previously described20. Five different
lentiviruses (Table 1) were used, including two NC
lentivirus (GFP-conjugated or red ﬂuorescent protein
(RFP)-conjugated), GFP-conjugated CTRP9 lentivirus
(LV. CTRP9) and RFP-conjugated lentivirus carrying
CRT-short hairpin RNA (shRNA) (shCRT), or AdipoR1shRNA. Cardiomyocytes were infected at ~100

Zhao et al. Cell Death and Disease (2018)9:723
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Fig. 1 Modulation of cardiac-derived CTRP9 affects left ventricular dysfunction and myocardial infarct size after MI/R. a–d Effect of cardiac
CTRP9 deﬁciency upon left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic
diameter (LVEDD), determined by echocardiography. e TTC/Evans blue double staining. The left ventricular (LV) area, the area at risk (AAR), and
ischemia area (IA) were measured. f–i Effect of cardiac CTRP9 overexpression upon LVEF, LVESD, and LVEDD. j Effect of cardiac CTRP9 overexpression
upon myocardial infarct size. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. sham group; #P < 0.05, ##P < 0.01 vs. MI/R + NC group.
N = 8–12

multiplicity of infection for 24 h in the presence of 5 μg/
ml Polybrene21,22. Cells were then bathed in normal culture medium. Stably transfected cells were selected via
GFP and RFP markers after 72 h transfection. The
transfective efﬁciency was determined by Western blot.
To investigate whether autocrine CTRP9 from cardiomyocytes contributed to SI/R injury, NCMs were infected
with LV. CTRP9 or NC for 4 h. NCMs were then cultured
for 48 h without serum, after the addition of CTRP9
antibody (LifeSpan Biosciences, Inc., LS-C373857) or IgG
(Cell Signaling Technology, Inc., #2729). To investigate
the role of cardiac-derived CTRP9 in PKA activation, a
PKA-speciﬁc inhibitor H89 (20 μM, Sigma-Aldrich,
371963-M) was employed.
Ofﬁcial journal of the Cell Death Differentiation Association

Western blot analysis

Mouse and rat LV tissue was harvested and lysed.
Protein concentrations were determined by BCA Protein
Assay Kit (Thermo Fisher Scientiﬁc, Inc., 23227). Proteins
were separated by electrophoresis and transferred to
polyvinylidene ﬂuoride membranes. The membranes were
blocked in Tris-buffered saline containing Tween-20 (pH
7.6) and 5% nonfat dry milk for 2 h, and subsequently
incubated overnight at 4 °C with primary antibodies to the
following proteins: Bcl-2 (#3498), Bax (#5023), GRP78
(#3177), caspase-12 (#2202), PKA (#4782), p-PKA
(Thr197), AMPK (#2532), p-AMPK (Thr172, #2531),
CREB (#9197), p-CREB (Ser133, #9198), Akt (#2967), pAkt (Thr308, #13038), ERK1/2 (#4696), p-ERK1/2

Zhao et al. Cell Death and Disease (2018)9:723
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Fig. 2 Cardiac-derived CTRP9 inhibits myocardial apoptosis subjected to MI/R injury. a TUNEL staining. Bar = 20 μm. b Caspase-3 activity.
c Western blot analysis of Bcl-2 and Bax expression. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. sham group; #P < 0.05, ##P < 0.01 vs.
MI/R + NC group. N = 5–8

(Thr202/Tyr204, #9106), Na+-K+-ATPase α1 (#23565),
β-actin (#8457) (all from Cell Signaling Technology, Inc.),
CTRP9 (LifeSpan Biosciences, Inc., LS-C373857), CRT
(Abcam, ab22683 and Santa Cruz, sc-373863), AdiopR1
(Abcam, ab126611), Calnexin (Santa Cruz, sc-23954),
KDEL ER marker (Santa Cruz, sc-58774), and GAPDH
(CMCTAG, Inc., AT0002). After washing, the membranes
were probed with appropriate secondary antibodies
(Zhongshan Company, ZB-2301, ZB-2305) at room temperature for 90 min. Protein bands were detected by BioRad Imaging System (Hercules), and normalized to βactin or GAPDH.
Ofﬁcial journal of the Cell Death Differentiation Association

Statistical analysis

All values in the text and ﬁgures are presented
as the mean ± standard error of mean (SEM) of n
independent experiments. The data were analyzed
using GraphPad Prism 6 statistic software (La Jolla,
CA, USA). Data were subjected to t test (two groups)
or one-way analysis of variance (ANOVA) (three or
more groups). Data of CTRP9-KO rat experiments
were determined by two-way ANOVA followed by
post hoc test with Holm adjustment. P values of
<0.05 (two-sided) were considered to be statistically
signiﬁcant.

Zhao et al. Cell Death and Disease (2018)9:723
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Fig. 3 Autocrine CTRP9 of cardiomyocyte origin protects against SI/R-induced apoptosis. a, b CTRP9 expression in NCMs after hypoxia for 12 h
followed by reoxygenation for 3 and 6 h. c–e Cardiomyocytes were infected with negative control (NC) or CTRP9 lentivirus (LV. CTRP9) and treated
with CTRP9 antibody (Ab) or control IgG. Cell apoptosis were determined by LDH release and caspase-3 activity. f, g Western blot analysis of Bcl-2 and
Bax expression. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. control group; #P < 0.05 vs. Reoxygen 3 h group; $$P < 0.01 between the
two groups connected by line. N = 3–6

Results
Cardiac-derived CTRP9 deﬁciency aggravates, while its
overexpression ameliorates, LV dysfunction after MI/R

To determine the effects of cardiac-derived CTRP9 in
the setting of MI/R injury, we ﬁrst utilized CTRP9 siRNA
(siCTRP9) to knock down its expression in the mouse
heart (Supplemental Fig. 1A). Compared to MI/R + NC
group, cardiac CTRP9-deﬁcient mice manifested lower
LV ejection fraction (LVEF) with an enlarged LV endsystolic diameter following MI/R (Fig. 1a–d). Inhibition of
cardiac CTRP9 increased mice myocardial infarct size
with 20.4% upregulation of the IA to AAR ratio (P < 0.05,
Fig. 1e). To conﬁrm the role of cardiac-derived CTRP9 in
MI/R injury, cardiac CTRP9 was speciﬁcally overexpressed (Supplemental Fig. 1B and 1C) without altering
Ofﬁcial journal of the Cell Death Differentiation Association

plasma CTRP9 level (Supplemental Fig. 1D). Cardiac
CTRP9 overexpression increased animal LVEF and
reduced LV end-diastolic diameter after MI/R (Fig. 1f–i).
Meanwhile, cardiac CTRP9 overexpression mice manifested smaller myocardial infarct size (P < 0.05, Fig. 1j).
Together, these data suggest that cardiac-derived CTRP9
directly protects against MI/R injury.
Cardiac-derived CTRP9 inhibits myocardial apoptosis
after MI/R

We next assessed myocardial apoptosis in MI/R injury
after genetic manipulation of cardiac CTRP9 expression.
TUNEL staining results revealed that cardiac CTRP9
overexpression inhibited (P < 0.01), while its deﬁciency
increased, cardiomyocyte apoptosis (P < 0.05) (Fig. 2a).

Zhao et al. Cell Death and Disease (2018)9:723
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Fig. 4 CTRP9 binds with CRT on the cell surface and in the cytoplasm of cardiomyocyte. a Co-immunoprecipitation (Co-IP) analysis of CRT (55
kDa band) with anti-CTRP9 antibody in left ventricular tissue lysate. b Co-IP analysis of CTRP9 (40 kDa band) with anti-CRT antibody in left ventricular
tissue lysate. c Fluorescent images of the colocalization of CTRP9 and CRT in neonatal rat cardiomyocytes (NCMs) exposed to SI/R injury. Green for
CTRP9, red for CRT, and blue for DAPI. Bar = 10 μm. d Detection of surface exposure of CRT in mouse heart tissue during MI/R injury, determined by
Western blot analysis

Caspase-3 activity manifested similar changes following
cardiac CTRP9 modulation (Fig. 2b). Furthermore,
cardiac CTRP9 overexpression activated anti-apoptotic
signaling via the increase of the Bcl-2 to Bax ratio,
which was suppressed in cardiac CTRP9-deﬁcient
mice (Fig. 2c). Together, these data indicate that
cardiac-derived CTRP9 exerts anti-apoptotic actions
after MI/R.
Autocrine CTRP9 of cardiomyocyte origin protects against
SI/R-induced apoptosis

To identify the origin of CTRP9 (autocrine vs. paracrine) responsive to SI/R injury, we analyzed CTRP9
expression in NCMs and MECs under SI/R. The level of
CTRP9 in MECs was unchanged after SI/R (P = 0.09,
Ofﬁcial journal of the Cell Death Differentiation Association

Supplemental Fig. 2B). However, the CTRP9 expression in
NCMs was decreased after 12 h hypoxia followed with 3 h
reoxygenation (P < 0.01), reaching a lower point at 42.3%
as reoxygenation time increased to 6 h (P < 0.01, Fig. 3a,
b). NCMs were infected with LV. CTRP9 (Supplemental
Fig. 1E and 1F) in the presence of CTRP9 antibody or
control IgG. SI/R-induced LDH release and caspase-3
activity were signiﬁcantly reduced by CTRP9 overexpression in NCMs (P < 0.01, respectively, Fig. 3c–e).
Moreover, cardiac CTRP9 overexpression approximately
tripled the Bcl-2 to Bax ratio (Fig. 3c, f, g). These effects
were abolished by CTRP9-neutralizing antibody (P < 0.01,
respectively, Fig. 3c–f). Together, these data suggest that
cardiomyocyte-derived CTRP9 inhibits SI/R-induced
apoptosis in an autocrine manner.

Zhao et al. Cell Death and Disease (2018)9:723

The CTRP9–CRT association is responsible for the antiapoptotic actions of cardiac-derived CTRP9

As previous reports demonstrate circulating CTRP9
protects against MI/R injury via an AdipoR1-dependent
mechanism, we determined cardiac AdipoR1 expression.
AdipoR1 levels were unchanged under cardiac CTRP9
modulation (Supplemental Fig. 3A). Instead, levels of
endoplasmic reticulum (ER) stress marker GRP78 were
elevated concomitantly with caspase-12 after MI/R. Cardiac CTRP9 overexpression suppressed, whereas its deﬁciency increased, GRP78 and caspase-12 expression
(Supplemental
Fig.
3B–D).
Notably,
coimmunoprecipitation (Co-IP) results demonstrated that
the ER molecular chaperone CRT immunoprecipitated
with anti-CTRP9 antibody in the LV tissue lysate (Fig. 4a,
55 kDa band) and vice versa (Fig. 4b, 40 kDa band). The
colocalization of CTRP9 and CRT in the cytoplasm of
normal NCMs was observed via double staining of CTRP9
(green) and CRT (red) via confocal microscopy (Supplemental Fig. 3E), demonstrating that CRT binds to CTRP9
in the cardiomyocyte. In NCMs subjected to SI/R injury
(12 h hypoxia followed by 3 h reoxygenation), a portion
of cytosolic CRT migrated into the cell surface and
combined with CTRP9 (Fig. 4c). The plasma membrane
CRT was also detected in mouse heart tissue after MI/R
injury (30 min ischemia followed by 3 h reperfusion,
Fig. 4d).
To further conﬁrm whether CRT or AdipoR1 was
involved in autocrine CTRP9 anti-apoptotic actions, lentivirus were utilized to knockdown CRT and AdipoR1
expression in NCM (Supplemental Fig. 4A–C). CRT
deﬁciency blunted cardiac-derived CTRP9’s response
to LDH release (P < 0.01, Fig. 5a, b) and caspase-3 activity
(P < 0.05, Fig. 5a, c). Moreover, CRT deﬁciency blunted
cardiac-derived CTRP9’s regulation of ER stress-related
apoptosis signaling pathway, demonstrated by increased
caspase-12 expression and decreased Bcl-2 to Bax ratio
(Fig. 5a, d–f). However, AdipoR1 deﬁciency had no signiﬁcant effects upon cardiac-derived CTRP9’s antiapoptotic actions (Fig. 5a–f). Together, these results
suggest that cardiac-derived CTRP9 protects against
cardiomyocyte apoptosis after SI/R via CRT binding.
CTRP9–CRT activates PKA–CREB axis to inhibit
cardiomyocyte apoptosis

To explore the downstream mechanism responsible for
CTRP9–CRT interaction against apoptosis, we analyzed
the activation of several pro-survival signaling pathways.
Cardiac CTRP9 overexpression signiﬁcantly activated
PKA phosphorylation at Thr197 (P < 0.01, Fig. 6a, b).
However, other signaling pathways, including AMPK,
ERK1/2, and Akt, typically activated by circulating
CTRP9 were not affected by cardiac CTRP9 modulation
(Fig. 6a, b). Our in vitro studies consistently demonstrated
Ofﬁcial journal of the Cell Death Differentiation Association
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that CTRP9 overexpression in NCMs signiﬁcantly phosphorylated PKA and its downstream effector CREB (P <
0.01, respectively, Fig. 6c, d), inhibited by CTRP9 antibody
(P < 0.05 and P < 0.01, respectively, Supplemental
Fig. 5A–D). These results indicate that cardiac-derived
CTRP9 mediates the PKA-CREB signaling pathway in an
autocrine manner.
To conﬁrm these ﬁndings, we utilized PKA-speciﬁc
inhibitor, H89, in vitro. Administration of H89 virtually
abolished PKA and CREB activation (P < 0.01, respectively, Fig. 6c, d). Meanwhile, H89 inhibited cardiacderived CTRP9’s response to SI/R-induced LDH release
(P < 0.01, Fig. 6e) and caspase-3 activity (P < 0.05, Fig. 6f).
Furthermore, CRT deﬁciency abrogated PKA and CREB
phosphorylation, while inhibition of AdipoR1 had no
effects (Fig. 6g–i). Together, these data demonstrate that
CTRP9–CRT initiates PKA-CREB signaling in cardiomyocyte to protect against MI/R injury.
CTRP9-KO rats exhibit exacerbated cardiac dysfunction
after MI/R, and cardiac CTRP9-speciﬁc overexpression
inhibits acute myocardial injury

To further conﬁrm the in vivo role of cardiac-derived
CTRP9, we generated CTRP9-KO rats upon an SD
background. Under baseline conditions, there were no
differences between 6-week-old CTRP9-KO and littermate wild-type (WT) rats (Supplemental Table 2). CTRP9
protein was undetectable in the heart of homozygous
CTRP9-KO rats. Then, a cardiac-speciﬁc expression of
CTRP9 was constructed via intra-myocardial injection of
LV. CTRP9 (Fig. 7a, b). CTRP9-KO rats exhibited lower
LVEF and larger myocardial infarct size, compared with
WT rats after MI/R injury. Cardiac CTRP9-speciﬁc
overexpression improved rat LVEF (P < 0.01, Fig. 7c)
and attenuated myocardial infarct size (P < 0.01, Fig. 7d).
TUNEL staining results revealed that CTRP9 ablation
signiﬁcantly increased myocardial apoptosis in the AAR
regions, while cardiac CTRP9-speciﬁc overexpression
reduced MI/R-induced apoptosis (Fig. 7e). Furthermore,
cardiac CTRP9-speciﬁc overexpression activated PKACREB signaling (Fig. 7f–h), consistent with in vitro
results.

Discussion

In the present study, we provide the ﬁrst evidence that
cardiac-derived CTRP9 exerts cardioprotection against
MI/R injury in an autocrine manner. As an APN paralog,
CTRP9 was initially identiﬁed as an adipokine16, regulating systemic metabolism and cardiovascular functions.
Circulating CTRP9 level decreases after MI/R, while
exogenous supplementation of recombinant globular
CTRP9 (gCTRP9) reverses cardiac dysfunction. We and
others have shown that CTRP9 is abundantly produced by
the heart itself, nearly 1.6-fold of plasma CTRP9 level14
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Fig. 5 CTRP9–CRT association is responsible for the anti-apoptotic actions of cardiac-derived CTRP9. a Effect of CRT or AdipoR1 deﬁciency on
LDH release. b Effect of CRT or AdipoR1 deﬁciency on caspase-3 activity. c–e Western blot analysis of caspase-12, Bcl-2, and Bax expression. Data are
presented as mean ± SEM. *P < 0.05, **P < 0.01 vs. control group; $P < 0.05, $$P < 0.01 between the two groups connected by line. N = 3–6

and 2-fold to 3-fold of subcutaneous fat tissue CTRP9
level17. However, the biologic role of cardiac-derived
CTRP9 remained heretofore unclear. In the current study,
we demonstrate that cardiac CTRP9 deﬁciency exacerbates, whereas its overexpression ameliorates, LV dysfunction and myocardial infarct size of mice in MI/R
injury. CTRP9-KO rats manifest similar resistant phenotype, while cardiac CTRP9-speciﬁc overexpression reverses myocardial function and improves cell survival.
Cardiac-derived CTRP9 inhibits MI/R-induced apoptosis, acting as a protective cardiokine.
A recent study demonstrated that myocardial endothelial cell-generated CTRP9 drives cardiac hypertrophy,
performing a maladaptive role in cardiac function17.
However, our in vitro results reveal that endothelial
CTRP9 expression is unchanged in SI/R. Instead, CTRP9
levels in NCMs decreased during SI/R injury, while
lentivirus-mediated endogenous CTRP9 overexpression
inhibits SI/R-induced apoptosis. These results conﬁrm
that autocrine CTRP9 of cardiomyocyte origin at least
partially responds to SI/R injury via inhibition of cell
apoptosis. The divergent roles of CTRP9 of different
origins may be due to different disease models activating
different cell types in response. Myocardial capillary
endothelial cells regulate cardiomyocyte growth, contributing to cardiac hypertrophy,8,23 whereas cardiomyocytes suffered from Ca2+ overload and mitochondrial
Ofﬁcial journal of the Cell Death Differentiation Association

permeability transition pore opening are involved in MI/R
injury24.
Next, we demonstrated that cardiac CTRP9 overexpression decreases, while its deﬁciency increases the
expression of ER stress-related apoptosis markers GRP78
and caspase-12 after MI/R. This is consistent with our
previous ﬁndings in the diabetic heart13. Notably, we
found that the ER molecular chaperone CRT, primarily
located in the ER lumen under physiological conditions,
migrates to the cell surface and nucleus of cardiomyocytes
subjected to SI/R. Cardiac-derived CTRP9 binds to CRT
both in the cytoplasm and on the cell surface of cardiomyocytes. Inhibition of CRT blunted cardiac-derived
CTRP9’s anti-apoptotic actions. CRT is characterized as
a molecular chaperone with functions of Ca2+ sensing,
glycoprotein folding, and major histocompatibility complex class I assembly25–27. CRT translocates from the ER
lumen to multiple subcellular localizations in response to
stress28–30. It modulates cell survival via ER stress regulation31–33. Cytosolic CRT regulates cell adhesion34, and
is involved in signal transduction events associated with
innate immunity35,36. Nuclear CRT functions as a nuclear
export receptor37,38. Cell surface CRT functions as a
receptor for C1q39, initiating the clearance of early
apoptotic cells for phagocytosis40,41. Karnabi et al.42
reported surface exposure of CRT in human fetal cardiomyocytes. In this regard, CRT may be a new receptor for
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Fig. 6 The PKA–CREB axis acts as the downstream of CTRP9–CRT interaction in MI/R injury. a, b Western blot analysis of PKA, AMPK, ERK1/2,
and Akt phosphorylation in vivo. c H89 administration inhibits PKA activation in vitro. d Effect of PKA inhibition upon CREB phosphorylation. e, f Effect
of PKA inhibition upon LDH release and caspase-3 activity. g–i Effect of CRT or AdipoR1 deﬁciency on PKA and CREB activation. Data are presented as
mean ± SEM. *P < 0.05, **P < 0.01 vs. control group; $P < 0.05, $$P < 0.01 between the two groups connected by line. N = 3–6

cardiomyocyte-derived CTRP9. It may assist CTRP9
folding and synthesis in cardiomyocytes, and promote the
internalization of autocrine CTRP9 during MI/R injury.
Conversely, previous studies have shown that circulating
CTRP9 regulates cardiovascular functions via AdipoR1dependent mechanisms. However, our present results
reveal that AdipoR1 expression is unchanged during
cardiac CTRP9 manipulation, and inhibition of AdipoR1
does not affect cardiac-derived CTRP9’s anti-apoptotic
effects after SI/R injury. A recent study identiﬁed Ncadherin as a speciﬁc receptor for CTRP9 acting upon
Ofﬁcial journal of the Cell Death Differentiation Association

adipose-derived mesenchymal stem cells43. Taking together, CTRP9 exerts cardioprotective functions at least
partially via AdipoR1-independent fashion.
Finally, the present study demonstrates that the
CTRP9–CRT interaction activates PKA-CREB pro-survival signaling. Previous results demonstrated that circulating CTRP9 exerts anti-inﬂammatory, anti-apoptotic,
and cardiovascular protective actions via activation of the
AdipoR1–AMPK axis11,12,15,44,45. However, we did not
ﬁnd evidence for differential activation of AMPK, ERK1/2,
or Akt in response to cardiac CTRP9 modulation
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Fig. 7 CTRP9-KO rat displays a dysfunctional phenotype following MI/R injury, and cardiac CTRP9-peciﬁc overexpression reverses acute
cardiac injury. a, b Cardiac CTRP9 expression in WT and CTRP9-KO rats receiving intra-myocardial injection of LV. CTRP9 or NC. c Representative
echocardiograms with LVEF assessment of WT and CTRP9-KO rats subjected to MI/R. d Myocardial infarct size. e TUNEL staining. Bar = 40 μm. f–h
Western blot analysis of PKA and CREB. Data are presented as mean ± SEM. $P < 0.05, $$P < 0.01 between the two groups connected by a line. N =
5–8

following MI/R injury. Instead, we observed signiﬁcant
phosphorylation of PKA (Thr197) and its downstream
effector CREB (Ser133) in cardiac CTRP9 overexpression
mice and rats, inhibited by functional neutralization of
autocrine CTRP9. Meanwhile, inhibition of PKA abrogated cardiac-derived CTRP9’s anti-apoptotic actions. It
might be that different CTRP9 isoforms mediate different
kinase activation. When produced by the heart, CTRP9 is
a full-length glycoprotein containing C1q globular
domain and N-terminal domains; the CTRP9 that circulates in the plasma does so in a globular domain
Ofﬁcial journal of the Cell Death Differentiation Association

isoform46. Co-IP results revealed that CRT binds to
full-length CTRP9 (40 kDa). Our previous study showed
that administration of gCTRP9 for 6 weeks after
MI activates PKA10 since sustained exogenous supplementation of gCTRP9 may increase both plasma and
myocardial CTRP9 levels43. Furthermore, our present
results suggest that CRT inhibition, not AdipoR1,
blunts PKA–CREB axis activation. Cardiac-derived
CTRP9 likely activates PKA-CREB signaling due to a
CRT-dependent regulation of intracellular Ca2+ inﬂux
after MI/R injury47,48.
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Fig. 8 Proposed mechanism responsible for autocrine CTRP9 of cardiomyocyte origin against MI/R injury. Brieﬂy, CTRP9 binds to ER
molecular chaperone CRT in the cytoplasm of cardiomyocyte under physiological conditions. When subjected to MI/R injury, CRT translocates to cell
surface and associates with autocrine CTRP9. CTRP9–CRT complex activates PKA-CREB pro-survival signaling and inhibits ER stress-related apoptotic
signaling, directly protecting against MI/R injury

In conclusion, autocrine CTRP9 of cardiomyocyte origin protects against MI/R injury via CRT binding.
Cardiac-derived CTRP9 activates PKA-CREB signaling
and inhibits ER stress-related apoptosis signaling during
MI/R injury (Fig. 8). These ﬁndings improve our understanding of CTRP9 of different cell origins in regulating
cardiomyocyte apoptosis after MI/R injury, and suggest
the potential value of therapeutic approaches targeting
cardiac-derived CTRP9 or CRT in the treatment and
prevention IHD and its complications.
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